

1 **Circulating microRNA profiles in early-stage osteoarthritis and rheumatoid arthritis**

2

3 Madhu Baghel<sup>1\*</sup>, Thomas Wilson<sup>1\*</sup>, Michelle Ormseth<sup>2,3</sup>, Patrick Yousif<sup>4</sup>, Ayad Alkhatib<sup>4</sup>, Alireza

4 Meysami<sup>4</sup>, Jason Davis<sup>5</sup>, Vasilios Moutzouros<sup>5</sup>, Shabana Amanda Ali<sup>1,6\*\*</sup>

5

6 **Affiliations**

7

8 <sup>1</sup>Bone and Joint Center, Henry Ford Health + Michigan State University Health Sciences,

9 Detroit, Michigan, USA

10 <sup>2</sup>Vanderbilt University Medical Center, Nashville, Tennessee, USA

11 <sup>3</sup>Tennessee Valley Health System, Nashville Campus VA Medical Center, Nashville,

12 Tennessee, USA

13 <sup>4</sup>Department of Rheumatology, Henry Ford Health, Detroit, Michigan, USA

14 <sup>5</sup>Department of Orthopedic Surgery, Henry Ford Health, Detroit, Michigan, USA

15 <sup>6</sup>Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA

16 \*Co-first authors

17 \*\*Corresponding author:

18 Shabana Amanda Ali, PhD

19 Bone and Joint Center, Henry Ford Health + Michigan State University Health Sciences,

20 6135 Woodward Avenue, Detroit MI 48202, USA

21 Email: [sali14@hfhs.org](mailto:sali14@hfhs.org)

22 Office: 313-874-8389

23

24

25

26

27 **Abstract**

28

29 **Background:** Osteoarthritis (OA) and rheumatoid arthritis (RA) are prevalent forms of arthritis.  
30 Early detection of OA and RA is challenging with existing methods, which can delay effective  
31 management. MicroRNAs are small molecules that have emerged as promising disease  
32 biomarkers with the potential to improve early detection and differentiation of arthritis subtypes.  
33 In this study we aimed to identify distinct circulating microRNAs in plasma from individuals with  
34 early OA and early RA, using an unbiased microRNA-sequencing approach.

35

36 **Methods:** Plasma samples were collected from three study groups including: (a) early OA (N=20),  
37 individuals with knee OA symptoms and radiographic Kellgren-Lawrence grade 0 or 1; (b) early  
38 RA (N=12), treatment-naïve individuals with <6 months of RA symptoms in any joint; and (c) non-  
39 OA/RA (N=44), individuals with no history of arthritis. Of these, N=62 samples were subjected to  
40 microRNA-sequencing and analysis using a previously optimized pipeline. Exploratory analyses  
41 were followed by a stepwise filtering approach to shortlist both known (documented in miRBase  
42 v22.1) and novel (predicted using bioinformatics) microRNAs. Prioritized microRNAs were then  
43 validated via real-time qPCR (RT-qPCR) in N=14 independent samples.

44

45 **Results:** Principal component analyses revealed clustering of early OA versus both early RA and  
46 non-OA/RA groups, but not between early RA and non-OA/RA. In early OA, n=170 differentially  
47 expressed (DE) microRNAs were identified compared to both early RA and non-OA/RA, while no  
48 significant differences were found between early RA and non-OA/RA. Of these DE microRNAs,  
49 stepwise filtering and RT-qPCR validation identified dysregulation of six known microRNAs  
50 between early OA and early RA. Of these six microRNAs, two were upregulated in early OA,  
51 including hsa-miR-16-5p and hsa-miR-29c-3p, and four were upregulated in early RA, including

52 hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400. Additionally, one  
53 novel microRNA sequence was found to be enriched in early OA and four in early RA.

54

55 **Conclusion:** We identified a total of six known and five novel circulating microRNAs that differ  
56 between early OA and early RA individuals. Validation of these microRNAs in independent  
57 cohorts is warranted to establish their biomarker potential for distinguishing individuals with early  
58 OA versus early RA.

59

60 **Keywords:**

61 Plasma; microRNA-sequencing; novel microRNAs; biomarker; human

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78 **Background**

79

80 Arthritis is a leading cause of joint pain and disability that encompasses over 100 subtypes (1).  
81 Among these, osteoarthritis (OA) and rheumatoid arthritis (RA) are the most common, with a  
82 global prevalence of 6.5% and 0.5-1%, respectively (2-4). Both conditions can affect a range of  
83 joints, from small phalangeal joints to larger weight-bearing joints, and both are driven by a  
84 multifactorial etiology involving genetic, epigenetic, and environmental factors (5, 6). OA is the  
85 most common type of non-autoimmune arthritis, primarily characterized by tissue destruction (5,  
86 7). RA is the most common type of autoimmune arthritis, primarily characterized by joint  
87 inflammation (8). Although the pathophysiology of OA and RA differs, the initial presentation (e.g.,  
88 symptoms such as joint pain) can overlap significantly, particularly in cases of single-joint disease  
89 (9-11). This creates a challenge for accurate diagnosis which is important in early stages of  
90 disease to enable timely implementation of appropriate interventions, including exercise for OA  
91 (12) and disease-modifying anti-rheumatic drugs (DMARDs) for RA (13).

92

93 Currently, diagnosis and staging criteria for OA rely on imaging, such as the Kellgren-Lawrence  
94 (KL) radiographic grading scale (11). For RA, diagnosis involves four domains as outlined by the  
95 American College of Rheumatology: serological testing [e.g., for rheumatoid factor (RF) and anti-  
96 citrullinated protein antibody (ACPA)], physical examination for joint swelling and tenderness,  
97 evaluation of symptom duration, and testing acute phase reactants like C-reactive protein (CRP)  
98 (14, 15). While these diagnostic methods are effective for established OA and RA, respectively,  
99 they are less reliable for detecting early-stage disease. Previous studies have defined early OA  
100 as individuals with KL grades 0 or 1 plus frequent joint pain lasting at least 4 weeks (16, 17), while  
101 early RA has been defined as treatment-naïve (i.e., no DMARD use) individuals with symptoms  
102 for <6 months and ACPA of an average 231.1 U/mL (range 24-2613.5 U/mL) (18). However,  
103 radiographic diagnosis of OA is dependent on identifying structural changes that are less apparent

104 in the early stages (11). For RA, serological markers like CRP lack specificity for RA-related  
105 inflammation and can be elevated in other conditions such as systemic lupus erythematosus or  
106 psoriatic arthritis (19, 20). Given these challenges, there is a need for biomarkers that can reliably  
107 detect and distinguish OA and RA in the early stages.

108

109 MicroRNAs have emerged as promising candidate biomarkers (21). These small non-coding RNA  
110 molecules are abundant and stable in peripheral blood, exhibit resistance to degradation, and  
111 show disease- and stage-specific profiles (22). Although previous studies have identified  
112 microRNAs involved in both OA and RA (23-25), to date only three studies have explored  
113 circulating microRNAs in early OA or early RA individuals. Briefly, Ali et al. compared early to late  
114 OA plasma utilizing microRNA-sequencing (16), Romo-García et al. compared early RA to healthy  
115 control serum with microRNA microarray (18), and Cunningham et al. compared “at risk” RA to  
116 healthy control serum using a microRNA multiplex panel (26). To the best of our knowledge, no  
117 studies have compared circulating microRNAs in early OA and early RA alongside non-OA/RA.

118

119 Advances in sequencing technology and bioinformatic tools have made microRNA-sequencing  
120 the current gold standard approach for unbiased and comprehensive microRNA profiling (27).  
121 Compared to methods such as microarray, sequencing enables high-throughput identification of  
122 microRNAs and discovery of novel microRNA transcripts (28, 29). Novel microRNAs are detected  
123 based on their predicted secondary structures and defined based on specific criteria (e.g., a lack  
124 of sequence homology with other species) (30). As a result, novel microRNAs can be highly  
125 specific to the biological contexts in which they are identified (29, 31). In this study, we aimed to  
126 use sequencing and bioinformatics to identify known and novel circulating microRNA signatures  
127 in early OA and early RA individuals.

128

129

## 130 **Methods**

131

### 132 **Study group characteristics**

133 An overview of the study groups is shown in **Figure 1A**. Plasma samples were obtained from the  
134 Henry Ford Health (HFH) OA Biobank, Nashville VA Medical Center, and the Osteoarthritis  
135 Initiative (OAI, <https://nda.nih.gov/oai>) for both microRNA-sequencing and validation experiments.  
136 We used established definitions for early OA (16, 17) and early RA (18). The early OA group  
137 included individuals with symptoms and knee KL grades of 0 or 1, as assessed by an orthopedic  
138 surgeon. Of N=20 early OA samples, N=12 were used for sequencing and N=8 for validation. The  
139 early RA group included treatment-naïve individuals with <6 months of RA symptoms in any joint,  
140 as assessed by a rheumatologist. The measured ACPA levels in this group were 42 to 1196 U/mL,  
141 which aligns with the previously reported range of 24 to 2613.5 U/mL for early RA (18). Of N=12  
142 early RA samples, N=6 were used for sequencing and N=6 for validation. The non-OA/RA group  
143 was obtained from the OAI “Control Cohort” and included individuals with no features of OA or  
144 RA. All N=44 non-OA/RA samples were used for sequencing. Clinicodemographic variables were  
145 collected as shown in **Table 1**, including age, sex, race, and body mass index (BMI). Institutional  
146 Review Board (IRB) approval was obtained from HFH (IRB #13995), the Nashville VA Medical  
147 Center (IRB #1643056 and IRB #1722175), and the OAI via the University of California, San  
148 Francisco (FWA approval # 00000068; IRB approval # 10-00532). Written informed consent was  
149 obtained from all participants before enrollment.

150

### 151 **Plasma collection**

152 Blood samples were collected in EDTA-coated vacutainers and fractionated by centrifugation as  
153 previously described (16). Plasma was aliquoted into 250 µL per cryovial, flash frozen with liquid  
154 nitrogen, and stored at -80°C until use. RNA was extracted from plasma using the miRNeasy  
155 Serum/Plasma Advanced Kit (QIAGEN Inc.) following the manufacturer’s guidelines. ACPA was

156 quantified in diluted plasma (dilution factor = 4), using the Human ACPA ELISA kit (abx257273;  
157 Abbexa LLC), following the manufacturer's guidelines. Absorbance was measured at 450 nm  
158 using a plate reader (PerkinElmer).

159

## 160 **MicroRNA-sequencing**

161 MicroRNA-sequencing and data analysis were performed for N=62 samples, according to  
162 previously published protocols (16, 28, 31). Briefly, RNA isolated from plasma was sequenced  
163 using a 75-base single-end read protocol at a depth of approximately  $17 \pm 2.5$  million  
164 reads/sample on an Illumina NextSeq2000 sequencer (**Figure 1B**). Raw microRNA sequences  
165 were aligned to miRBase v22.1 (32) and the human reference genome (vGRCh38; **Figure 1C**).  
166 Next, we filtered for abundant microRNAs with at least 10 counts-per-million (CPM) in two or more  
167 samples, and normalized counts to total counts (16, 28). Differential expression analysis between  
168 groups was performed in a pairwise manner using a quasi-likelihood negative binomial model with  
169 trended dispersions with the edgeR package (v3.40.2; **Figure 1D,E**).

170

## 171 **Bioinformatics**

172 Novel microRNA sequences were identified using miRDeep2 (30) as previously described (16,  
173 31). Briefly, raw reads were aligned to the human reference genome (vGRCh38) with sequences  
174 included in the miRBase v22.1 human and hairpin microRNA databases excluded. Candidate  
175 novel microRNAs were subsequently filtered by significant randfold value ( $p < 0.05$ ), a measure of  
176 microRNA secondary structure stability, and by lack of homology with known mature microRNA  
177 sequences in mice. Prioritized novel microRNA sequences were subjected to NCBI nucleotide  
178 Basic Local Alignment Search Tool (BLASTN; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>) against  
179 *Homo sapiens* sequences. The search considered 100% query cover, 100% identity match, and  
180 no set E-value.

181

## 182 **MicroRNA real-time polymerase chain reaction (RT-qPCR)**

183 MicroRNA RT-qPCR was performed in N=8 early OA and N=6 early RA independent plasma  
184 samples (**Figure 1F**), as previously described (33, 34). Briefly, a poly(A) tail was added to the  
185 microRNA with poly(A) polymerase (M0276L; NEB), followed by reverse transcription (RT) for the  
186 synthesis of cDNA using poly(T)-containing RT primers. The resulting cDNA was amplified using  
187 a QuantStudio 7 Pro Real-Time PCR System (Applied Biosystems), with custom microRNA  
188 oligonucleotides (Sigma-Aldrich) as specified in **Supplemental Table 1** and SYBR Green dye  
189 (Bio-Rad). Hsa-miR-24-3p was used as an endogenous control as previously done (16, 28).

190

## 191 **Statistical analyses**

192 All data analysis was performed using R statistical software (v.4.2.0). For microRNA discovery  
193 and validation, a power calculation estimated a minimum sample size of N=6/group to detect a  
194 differential expression threshold of fold-change  $\pm 2$ , at 80% power. Principal component analysis  
195 (PCA) was performed on variance-stabilized transformed counts. Heatmaps were plotted using  
196 z-score-transformed CPM. RT-qPCR data were analyzed using the delta-delta-Ct method (35).  
197 Statistical significance was determined by false discovery rate (FDR) correction  $\leq 0.05$  for  
198 microRNA-sequencing, and two-tailed Student's T-test for RT-qPCR analyses at  $p \leq 0.05$ .

199

## 200 **Results**

201

### 202 **Exploratory analyses of microRNAs in early OA and early RA plasma**

203 To discover circulating microRNAs dysregulated in either early OA or early RA (**Figure 1G**), we  
204 performed microRNA-sequencing on N=62 plasma samples as shown in **Table 1**. Samples were  
205 matched for clinicodemographic variables as closely as possible, though significant differences in  
206 age and race across groups were noted (**Table 1**). After sequencing, read alignment to miRBase  
207 and the human reference genome resulted in raw counts for 2656 mature microRNAs. Data



208 analyses were performed in a pairwise manner, leading to three comparisons: (1) early OA versus  
209 early RA, (2) early OA versus non-OA/RA and (3) early RA versus non-OA/RA. First, we filtered  
210 for microRNAs with >10 CPM in two or more samples (within each comparison), resulting in 285  
211 abundant microRNAs for early OA versus early RA, 364 for early OA versus non-OA/RA, and 354  
212 for early RA versus non-OA/RA. Next, we performed PCA to identify components that account for  
213 the variance within the counts. PCA plots showed distinct clustering between early OA and both  
214 early RA (**Figure 2A**) and non-OA/RA (**Figure 2B**), while no clustering was observed between  
215 early RA and non-OA/RA (**Figure 2C**). Despite the significant differences in age and race across  
216 groups (**Table 1**), no clustering was observed when classifying samples by age, sex, BMI, or race  
217 (**Supplemental Figure 1**), suggesting that these variables did not significantly impact microRNA  
218 counts. Following this, we performed unsupervised hierarchical clustering of microRNA counts for  
219 each pairwise comparison. Using heatmaps to visualize the results, we observed patterns of high  
220 and low levels of microRNAs in both the early OA versus early RA (**Supplemental Figure 2A**)  
221 and early OA versus non-OA/RA comparisons (**Supplemental Figure 2B**); however, no  
222 appreciable patterns were observed in the early RA versus non-OA/RA comparison  
223 (**Supplemental Figure 2C**). Finally, we performed pairwise differential expression analyses to  
224 identify significant differences in microRNAs in each comparison. At  $FDR \leq 0.05$ , we identified 170  
225 differentially expressed (DE) microRNAs between early OA and early RA (**Figure 2D**) and 305  
226 DE microRNAs for early OA versus non-OA/RA (**Figure 2E**); however, no significant differences  
227 were found between early RA and non-OA/RA (**Figure 2F**). Taken together, these results suggest  
228 there are distinct circulating microRNAs in early OA versus both early RA and non-OA/RA, but  
229 not between early RA and non-OA/RA.

230

### 231 **Stepwise filtering of microRNAs dysregulated in early OA and early RA**

232 To systematically identify dysregulated microRNAs associated with early OA and early RA, we  
233 implemented a stepwise filtering approach. The first steps retained abundant microRNAs (**Figure**

234 **3A, Criterion 1**) and DE microRNAs (**Figure 3A, Criterion 2**) for each pairwise comparison, as  
235 described above. We then compared the lists of DE microRNAs to identify those that were shared  
236 and found all 170 DE microRNAs identified in the early OA versus early RA comparison were also  
237 dysregulated in the early OA versus non-OA/RA comparison. Since no additional DE microRNAs  
238 were detected between early RA and non-OA/RA, we focused on the 170 DE microRNAs in early  
239 OA versus both early RA and non-OA/RA (**Figure 3A, Criterion 2**). Next, we filtered for  
240 microRNAs that were consistently up- or downregulated across samples in a group relative to  
241 their median levels in the comparison group (**Figure 3A, Criterion 3**). For early OA, 13  
242 microRNAs were upregulated and 132 downregulated in 100% of samples compared to their  
243 median counts in early RA group. Of these, all 13 upregulated and 128 of the 132 downregulated  
244 microRNAs showed the same trend when compared to median counts in the non-OA/RA group  
245 (**Figure 3A, Criterion 3**). For early RA, 137 microRNAs were upregulated and 15 downregulated  
246 in 100% of samples versus their median counts in the early OA group. Since no microRNAs met  
247 the 100% threshold in the early RA versus non-OA/RA comparison, we relaxed this threshold to  
248  $\geq 83\%$  of early RA samples and identified two upregulated (hsa-miR-11400, hsa-miR-21-5p) and  
249 two downregulated (hsa-miR-660-5p, hsa-miR-29c-3p) microRNAs (**Figure 3A, Criterion 3**).  
250 These four microRNAs represented our shortlisted panel for early RA (**Supplemental Table 2**).  
251 To refine the list of microRNAs for early OA, we performed an additional filtering step to select  
252 microRNAs with average logCPM  $\geq 10$  and logFC  $\geq 1$  or  $\leq -2.5$  in early OA versus early RA. This  
253 resulted in a shortlisted panel of four upregulated (hsa-miR-144-3p, hsa-miR-486-3p, hsa-miR-  
254 486-5p, hsa-miR-16-5p) and four downregulated (hsa-miR-744-5p, hsa-miR-382-5p, hsa-miR-  
255 3074-5p, hsa-miR-142-3p) microRNAs for early OA (**Figure 3A, Criterion 4; Supplemental**  
256 **Table 3**). In sum, this filtering approach shortlisted 12 microRNAs with distinct profiles in early OA  
257 and early RA plasma (**Figure 3B**).

258

259 **MicroRNA validation in independent early OA and early RA samples**

260 After shortlisting 12 microRNAs (**Figure 3**), we next sought to validate their levels in independent  
261 plasma samples using RT-qPCR. We focused on early OA versus early RA as our most clinically  
262 relevant comparison and measured the levels of each microRNA in N=8 early OA and N=6 early  
263 RA plasma samples (**Supplemental Table 4**). Of the 12 microRNAs, six showed patterns  
264 consistent with our microRNA-sequencing results. Among these, hsa-miR-16-5p and hsa-miR-  
265 29c-3p were elevated in early OA (**Figure 4A,B**), while hsa-miR-774-5p, hsa-miR-382-5p, hsa-  
266 miR-3074-5p, and hsa-miR-11400 were elevated in early RA (**Figure 4C-F**). The six remaining  
267 microRNAs either did not reach statistical significance or showed trends opposite to our  
268 sequencing data (**Supplemental Figure 3**). Overall, these results prioritize hsa-miR-16-5p, hsa-  
269 miR-29c-3p, hsa-miR-774-5p, hsa-miR-382-5p, hsa-miR-3074-5p, and hsa-miR-11400 as six  
270 circulating microRNAs that are different between early OA and early RA (**Figure 1F**).

271

#### 272 **Novel microRNA discovery in early OA and early RA**

273 We next used established protocols to discover novel microRNAs in our sequencing dataset (16,  
274 31). This approach identified 1257 unique predicted novel microRNA sequences that were  
275 present in at least one early OA or early RA sample, had a randfold p-value of <0.05, and showed  
276 no homology with known microRNA sequences in mice. To refine this list, we retained novel  
277 microRNAs present in  $\geq 50\%$  of either early OA or early RA samples, resulting in three and ten  
278 novel microRNAs, respectively (**Table 2**). BLASTN analysis confirmed the human origin of all 13  
279 novel microRNA sequences, demonstrating 100% identity match and 100% query coverage when  
280 compared to *Homo sapiens* sequences. Looking for novel microRNAs that were enriched in early  
281 OA, we identified Novel miRNA EOA 2 in  $\geq 75\%$  of early OA samples and <25% of both early RA  
282 and non-OA/RA samples (**Table 2**). Meanwhile, four novel microRNAs (Novel miRNA ERA 2, 3,  
283 4, and 7) were present in  $\geq 50\%$  of early RA samples, and completely absent in early OA samples  
284 (**Table 2**). We therefore prioritized these five novel microRNAs as the most distinct between early  
285 OA and early RA.

## 286 **Discussion**

287

288 Detecting early OA and early RA in clinical settings can be challenging since current diagnostic  
289 tools work best for established disease. Distinguishing early OA from early RA can also be  
290 challenging given the overlap in the initial presentation. These challenges point to the need for  
291 reliable, minimally invasive biomarkers to support accurate diagnosis and timely intervention.  
292 There is mounting evidence demonstrating the utility of non-coding RNAs as disease biomarkers  
293 (21, 25). In this study, we explore the potential of circulating microRNAs by performing microRNA-  
294 sequencing on plasma samples from individuals with early OA, early RA, and non-OA/RA. We  
295 observe distinct patterns of microRNAs between early OA and both early RA and non-OA/RA, but  
296 no significant differences between early RA and non-OA/RA. With stepwise filtering and real-time  
297 PCR validation, we prioritize a panel of six known microRNAs and five novel microRNAs as  
298 candidates to differentiate early OA from early RA.

299

300 Among the strengths of this study is the customized microRNA-sequencing analysis pipeline and  
301 systematic filtering approach we applied (16, 31). A common pitfall of profiling studies is the  
302 reliance on single thresholds, such as p-values or fold-changes, to select targets of interest.  
303 These thresholds can vary significantly between studies (36, 37), leading to irreproducible results;  
304 moreover, this strategy risks prioritizing biomarker candidates with statistical significance but not  
305 biological relevance. To overcome this, we designed a filtering approach to prioritize microRNAs  
306 with properties that would make strong biomarkers. First, we selected high abundance  
307 microRNAs to increase the likelihood their presence would be detectable in a general population.  
308 This is important because many microRNAs have low to no counts in a sequencing dataset, so  
309 while their fold change may be statistically significant, they may not play a biologically relevant  
310 role (38). Second, we performed pairwise differential expression analyses to consider each Group  
311 1 to both Groups 2 and 3. This allowed us to prioritize microRNAs in early OA versus both early

312 RA and non-OA/RA, and to find that microRNAs in early RA were different compared to early OA,  
313 not but non-OA/RA. Third, to counter the heterogeneity inherent to human biospecimens, we  
314 selected DE microRNAs that showed an increase or decrease across the majority of individual  
315 samples in a group. This allowed us to prioritize microRNAs with consistent trends and a greater  
316 likelihood of being reproducible. Interestingly, nearly all the microRNAs in the early OA group  
317 showed exclusive up- or downregulation compared to both early RA and non-OA/RA, suggesting  
318 a robust microRNA signature for early OA. As a fourth and final step to refine this early OA  
319 signature, we applied thresholds based on abundance and fold-change to retain microRNAs with  
320 the greatest difference between groups. Importantly, these filtering criteria were designed to  
321 prioritize microRNAs with biomarker potential, which means other criteria may be more  
322 appropriate for microRNA studies with different objectives.

323

324 Previous studies have reported circulating microRNAs in early OA and early RA, including seven  
325 plasma microRNAs associated with early OA (16) and seven serum microRNAs associated with  
326 early RA (18) or “at risk” RA (26). Notably, there was no overlap between these 14 microRNAs  
327 and the microRNAs shortlisted in the current study; however, 12 of the 14 microRNAs showed a  
328 significant difference in at least one of our three pairwise comparisons. From Ali et al. (16), seven  
329 microRNAs were elevated in early versus late radiographic knee OA plasma; among these, four  
330 were significantly downregulated in our early OA samples compared to both early RA and non-  
331 OA/RA (hsa-miR-191-3p, hsa-miR-199a-5p, hsa-miR-335-5p, and hsa-miR-671-3p). From  
332 Romo-García et al. (18), hsa-miR-361-5p was reported to be elevated in early RA serum  
333 compared to non-RA controls, and it was significantly upregulated in our early RA samples  
334 compared to early OA, but not to non-OA/RA. From Cunningham et al. (26), six microRNAs were  
335 upregulated in serum from “at risk” RA individuals (symptomatic with positive ACPA or RF but  
336 without clinical synovitis or raised CRP) versus healthy controls (26). Of these, five were found to  
337 be significantly upregulated in our early RA samples compared to early OA, but not to non-OA/RA.

338 Overall, the inconsistencies between previous literature and our findings are not unexpected given  
339 the variations in study groups, sample types, and analytical approaches. This underscores the  
340 need for standardized methodologies in biomarker discovery.

341  
342 Given their lack of previous documentation, novel microRNAs are inherently valuable as potential  
343 disease-specific biomarkers (30). Ali et al. (16) previously reported four novel microRNAs that  
344 were enriched in early OA. Of these, two sequences (novel\_miRNA\_2 and novel\_miRNA\_3) were  
345 found in our dataset but did not meet our filtering criteria, as they were present in <50% of early  
346 OA samples. To our knowledge, no studies to date have reported novel microRNAs in early RA.  
347 We present four novel microRNA candidates that merit further investigation as biomarkers for  
348 early RA, including characterization to verify their authenticity as microRNAs.

349  
350 Relationships between circulating microRNAs and pathological processes have been reported in  
351 arthritis (39, 40), suggesting circulating microRNAs can reflect local disease status. In early OA  
352 plasma, we found elevated levels of hsa-miR-16-5p and hsa-miR-29c-3p. Previous studies have  
353 reported increased levels of hsa-miR-16 in OA plasma versus non-OA controls (41), and  
354 decreased levels in early RA serum versus established RA (42). It is also upregulated in serum  
355 from RA individuals following treatment with anti-inflammatory agents (43). In terms of tissue  
356 functions, hsa-miR-16-5p has mechanistic connections to cartilage degradation in OA (41). While  
357 hsa-miR-29c-3p has not been previously explored in OA or RA circulation, elevated levels are  
358 found in late OA versus early OA synovial fluid (44). These findings are not directly comparable  
359 to ours, but inverse trends between circulating and local microRNA levels have been previously  
360 reported (40, 45). In early RA plasma, we found elevated levels of hsa-miR-382-5p, hsa-miR-774-  
361 5p, hsa-miR-3074-5p, and hsa-miR-11400. Little is known about the role of these microRNAs in  
362 arthritis, with only one study examining the behavior of hsa-miR-382-5p in RA fibroblast-like

363 synoviocytes (46). As such, the current study is the first to propose these four microRNAs as  
364 potential biomarkers for early RA.

365

366 To note the limitations of this study, our sample sizes were sufficient to detect significant  
367 microRNAs at  $FDR \leq 0.05$  but were not sufficient to support the testing of predictive models (47,  
368 48). Future studies with larger cohorts are required to evaluate the sensitivity and specificity of  
369 our prioritized microRNAs as biomarkers for early OA and early RA. Second, the microRNA  
370 signature we identify for early OA appears to be more robust than that identified for early RA,  
371 given the lack of differences between early RA and non-OA/RA. While previous studies report  
372 differences between early RA and healthy controls (18, 26), the utility of our study lies primarily in  
373 the comparison between early RA and early OA to ultimately support differentiation of these cases  
374 in clinical settings. Finally, we did not define OA by the number of joints involved, or RA by the  
375 specific joints involved, which may influence microRNA patterns. Future microRNA biomarker  
376 discovery studies are needed to compare single-joint knee OA versus RA, and RA versus other  
377 inflammatory conditions with overlapping serological markers.

378

### 379 **Conclusion**

380 To our knowledge, this is the first study that profiles circulating microRNAs in early OA, early RA,  
381 and non-OA/RA individuals using microRNA-sequencing. With a tailored approach to data  
382 analysis, we prioritized 11 circulating microRNAs (six known and five novel) that are associated  
383 with early OA and early RA. These findings suggest there is potential for circulating microRNAs  
384 to serve as minimally invasive biomarkers for early OA and early RA, including as composite  
385 biomarkers on panels that include proteins. With further research in larger cohorts, these  
386 microRNAs can be developed into a diagnostic test to improve arthritis care.

387

388



389 **List of abbreviations**

390

391 ACPA: Anti-citrullinated protein antibody

392 BLASTN: nucleotide Basic Local Alignment Search Tool

393 BMI: Body mass index

394 CPM: Counts per million

395 CRP: C-reactive protein

396 DE: Differentially expressed

397 DMARDs: Disease-modifying anti-rheumatic drugs

398 FC: Fold-change

399 FDR: False discovery rate

400 KL: Kellgren-Lawrence

401 PCA: Principal component analysis

402 RA: Rheumatoid arthritis

403 RF: Rheumatoid factor

404 RT-qPCR: Real time polymerase chain reaction

405 OA: Osteoarthritis

406

407 **Declarations**

408

409 **Ethics approval and consent to participate**

410 All participants provided written informed consent to be included in this study. The study protocol

411 followed guidelines set by the Henry Ford Health Institutional Review Board (IRB #13995).

412 Additional ethics approval was provided by the VA Tennessee Healthcare System (IRB #1643056

413 and IRB #1722175), and the OAI via University of California, San Francisco (FWA approval #

414 00000068; IRB approval # 10-00532).



415

416 **Availability of data and materials**

417 The microRNA-sequencing datasets generated during this study were deposited in the Gene  
418 Expression Omnibus database and will be released following peer-reviewed publication.

419

420 **Funding**

421 Funding for this study was provided by competitive grants awarded to SAA from the Pfizer Global  
422 Medical Grants (#72538937) and the University of Toronto McLaughlin Centre Accelerator Grant  
423 (#MC-2022-06), and to MO by the Merit award (#I01CX002356) from the US Department of  
424 Veterans Affairs and the Discovery award (#HT9425-23-1-0044) from the Department of Defense,  
425 Peer Reviewed Medical Research Program.

426

427 **Competing Interests**

428 SAA declares that she has filed a US Provisional Patent Application no. 63/033,463 titled  
429 *Circulating MicroRNAs in Knee Osteoarthritis and Uses Thereof*. All other authors declare no  
430 competing interests.

431

432 **Author contributions**

433 MB, TGW, and SAA were involved in study conception and design. MB and TGW performed  
434 experimental work and data acquisition. JD, VM, MO, PY, AA, AM, MB and TGW contributed to  
435 biospecimen collection. MB, TGW, and SAA performed data analysis, interpretation, and drafted  
436 the manuscript. All authors contributed to manuscript revisions and approved the final version.

437

438

439

440

441 **References**

- 442 1. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-  
443 Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015.  
444 MMWR Morb Mortal Wkly Rep. 2017;66(9):246-53.
- 445 2. Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, et al. Global,  
446 regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic  
447 analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology*.  
448 2023;5(9):e508-e22.
- 449 3. Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence Trends of Site-  
450 Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study  
451 2019. *Arthritis Rheumatol*. 2022;74(7):1172-83.
- 452 4. Kurdi AJ, Voss BA, Tzeng TH, Scaife SL, El-Othmani MM, Saleh KJ. Rheumatoid  
453 Arthritis vs Osteoarthritis: Comparison of Demographics and Trends of Joint Replacement Data  
454 from the Nationwide Inpatient Sample. *Am J Orthop (Belle Mead NJ)*. 2018;47(7).
- 455 5. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the  
456 joint as an organ. *Arthritis Rheum*. 2012;64(6):1697-707.
- 457 6. Ospelt C, Gay S, Klein K. Epigenetics in the pathogenesis of RA. *Semin Immunopathol*.  
458 2017;39(4):409-19.
- 459 7. Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair,  
460 regeneration, and transplantation. *Instr Course Lect*. 1998;47:487-504.
- 461 8. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet*.  
462 2016;388(10055):2023-38.
- 463 9. Mandl LA. Osteoarthritis year in review 2018: clinical. *Osteoarthritis Cartilage*.  
464 2019;27(3):359-64.
- 465 10. Ostrowska M, Maslinski W, Prochorec-Sobieszek M, Nieciecki M, Sudol-Szopinska I.  
466 Cartilage and bone damage in rheumatoid arthritis. *Reumatologia*. 2018;56(2):111-20.


- 467 11. Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence  
468 Classification of Osteoarthritis. *Clin Orthop Relat Res*. 2016;474(8):1886-93.
- 469 12. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American  
470 College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of  
471 the Hand, Hip, and Knee. *Arthritis Care Res (Hoboken)*. 2020;72(2):149-62.
- 472 13. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021  
473 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.  
474 *Arthritis Care Res (Hoboken)*. 2021;73(7):924-39.
- 475 14. Fc A. The American Rheumatism Association 1987 revised criteria for the classification  
476 of rheumatoid arthritis. *Arthritis Rheum*. 1988;31:315-24.
- 477 15. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010  
478 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European  
479 League Against Rheumatism collaborative initiative. *Arthritis Rheum*. 2010;62(9):2569-81.
- 480 16. Ali SA, Gandhi R, Potla P, Keshavarzi S, Espin-Garcia O, Shestopaloff K, et al.  
481 Sequencing identifies a distinct signature of circulating microRNAs in early radiographic knee  
482 osteoarthritis. *Osteoarthritis Cartilage*. 2020.
- 483 17. Luyten FP, Bierma-Zeinstra S, Dell'Accio F, Kraus VB, Nakata K, Sekiya I, et al. Toward  
484 classification criteria for early osteoarthritis of the knee. *Semin Arthritis Rheum*. 2018;47(4):457-  
485 63.
- 486 18. Romo-Garcia MF, Bastian Y, Zapata-Zuniga M, Macias-Segura N, Castillo-Ortiz JD,  
487 Lara-Ramirez EE, et al. Identification of putative miRNA biomarkers in early rheumatoid arthritis  
488 by genome-wide microarray profiling: A pilot study. *Gene*. 2019;720:144081.
- 489 19. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between  
490 acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid  
491 arthritis. *Ann Clin Lab Sci*. 2004;34(4):423-6.

- 492 20. Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know.  
493 J R Soc Med. 2004;97(9):421-4.
- 494 21. Rocha FAC, Ali SA. Soluble biomarkers in osteoarthritis in 2022: year in review.  
495 Osteoarthritis Cartilage. 2023;31(2):167-76.
- 496 22. Bottani M, Banfi G, Lombardi G. The Clinical Potential of Circulating miRNAs as  
497 Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated  
498 Bone Diseases. Biomolecules. 2020;10(4).
- 499 23. Zhang M, Lygrisse K, Wang J. Role of MicroRNA in Osteoarthritis. J Arthritis. 2017;6(2).
- 500 24. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid  
501 arthritis: From pathogenesis to clinical impact. Autoimmun Rev. 2019;18(11):102391.
- 502 25. Ali SA, Peffers MJ, Ormseth MJ, Jurisica I, Kapoor M. The non-coding RNA interactome  
503 in joint health and disease. Nat Rev Rheumatol. 2021;17(11):692-705.
- 504 26. Cunningham CC, Wade S, Floudas A, Orr C, McGarry T, Wade S, et al. Serum miRNA  
505 Signature in Rheumatoid Arthritis and "At-Risk Individuals". Front Immunol. 2021;12:633201.
- 506 27. Dedeoglu BG. High-throughput approaches for microRNA expression analysis. Methods  
507 Mol Biol. 2014;1107:91-103.
- 508 28. Ali SA, Espin-Garcia O, Wong AK, Potla P, Pastrello C, McIntyre M, et al. Circulating  
509 microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee  
510 osteoarthritis in the Osteoarthritis Initiative cohort. Ther Adv Musculoskelet Dis.  
511 2022;14:1759720X221082917.
- 512 29. Wake C, Labadorf A, Dumitriu A, Hoss AG, Bregu J, Albrecht KH, et al. Novel microRNA  
513 discovery using small RNA sequencing in post-mortem human brain. BMC Genomics.  
514 2016;17(1):776.
- 515 30. Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately  
516 identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids  
517 Res. 2012;40(1):37-52.

- 518 31. Potla P, Ali SA, Kapoor M. A bioinformatics approach to microRNA-sequencing analysis.  
519 Osteoarthritis and Cartilage Open. 2021;3(1).
- 520 32. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using  
521 deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68-73.
- 522 33. Busk PK. A tool for design of primers for microRNA-specific quantitative RT-qPCR. BMC  
523 Bioinformatics. 2014;15:29.
- 524 34. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs  
525 with DNA primers. BMC Biotechnol. 2011;11:70.
- 526 35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time  
527 quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. Methods. 2001;25(4):402-8.
- 528 36. Zhou Y, Wang Z, Chen X, Zhang J, Yang L, Liu S, et al. Identification of differentially  
529 expressed miRNAs and mRNAs in synovial of osteoarthritis via RNA-sequencing. BMC Med  
530 Genet. 2020;21(1):46.
- 531 37. Maunder D, Brown PM, Barron-Millar B, Lendrem DW, Naamane N, Macdonald J, et al.  
532 Micro-RNA content of circulating extracellular vesicles in early rheumatoid arthritis as  
533 biomarkers and mediators of methotrexate efficacy. Rheumatology (Oxford). 2024;63(8):2259-  
534 67.
- 535 38. Chen Y, Lun AT, Smyth GK. From reads to genes to pathways: differential expression  
536 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline.  
537 F1000Res. 2016;5:1438.
- 538 39. Ramos YFM, Coutinho de Almeida R, Lakenberg N, Suchiman E, Mei H, Kloppenburg  
539 M, et al. Circulating MicroRNAs Highly Correlate to Expression of Cartilage Genes Potentially  
540 Reflecting OA Susceptibility-Towards Identification of Applicable Early OA Biomarkers.  
541 Biomolecules. 2021;11(9).
- 542 40. Wilson TG, Baghel M, Kaur N, Moutzouros V, Davis J, Ali SA. Characterization of miR-  
543 335-5p and miR-335-3p in human osteoarthritic tissues. Arthritis Res Ther. 2023;25(1):105.

- 544 41. Borgonio Cuadra VM, Gonzalez-Huerta NC, Romero-Cordoba S, Hidalgo-Miranda A,  
545 Miranda-Duarte A. Altered expression of circulating microRNA in plasma of patients with  
546 primary osteoarthritis and in silico analysis of their pathways. *PLoS One*. 2014;9(6):e97690.
- 547 42. Dunaeva M, Blom J, Thurlings R, Pruijn GJM. Circulating serum miR-223-3p and miR-  
548 16-5p as possible biomarkers of early rheumatoid arthritis. *Clin Exp Immunol*. 2018;193(3):376-  
549 85.
- 550 43. Castro-Villegas C, Perez-Sanchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limon P, et  
551 al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis  
552 patients treated with anti-TNFalpha. *Arthritis Res Ther*. 2015;17(1):49.
- 553 44. Li YH, Tavallae G, Tokar T, Nakamura A, Sundararajan K, Weston A, et al.  
554 Identification of synovial fluid microRNA signature in knee osteoarthritis: differentiating early-  
555 and late-stage knee osteoarthritis. *Osteoarthritis Cartilage*. 2016;24(9):1577-86.
- 556 45. Malakootian M, Gholipour A, Oveisee M. Comprehensive bioinformatics analysis of key  
557 miRNAs and signaling pathways in the body fluids of human knee osteoarthritis. *Cell Mol Biol*  
558 (Noisy-le-grand). 2023;69(12):88-97.
- 559 46. Meng D, Pan W, Li J. The Role of miR-382-5p in Rheumatoid Arthritis: An In Vitro Study  
560 with Fibroblast-Like Synoviocytes. *Journal of Biomaterials and Tissue Engineering*.  
561 2020;10:169-75.
- 562 47. Kok MGM, de Ronde MWJ, Moerland PD, Ruijter JM, Creemers EE, Pinto-Sietsma SJ.  
563 Small sample sizes in high-throughput miRNA screens: A common pitfall for the identification of  
564 miRNA biomarkers. *Biomol Detect Quantif*. 2018;15:1-5.
- 565 48. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the  
566 number of events per variable in logistic regression analysis. *J Clin Epidemiol*.  
567 1996;49(12):1373-9.
- 568
- 569


570 **Main display items**



571 **Figure 1. Overview of study design.** (A) The study included three groups defined by  
 572 predetermined inclusion and exclusion criteria. (B) MicroRNA-sequencing was performed on  
 573 N=62 plasma samples. (C) Data were processed using an established pipeline (31). (D)  
 574 Exploratory analyses included principal component analysis (PCA). (E) Stepwise filtering was  
 575 performed to shortlist microRNAs. (F) Validation experiments in N=14 independent samples  
 576 prioritized six microRNAs. (G) Dysregulated known and novel microRNAs may be used to  
 577 distinguish individuals with early OA or early RA.



578



579 **Figure 2. Distinct circulating microRNAs are present in early OA and early RA.** (A-C)  
580 Principal component analyses showing clustering of samples when stratified by cohort. Each point  
581 represents a sample. Each axis represents the percentage variance for the principal component  
582 (PC). (D-F) Volcano plots showing differentially expressed microRNAs in each comparison, with  
583  $FDR \leq 0.05$  (horizontal line). Each dot represents a microRNA.

584

585

586

587

588

589

590


591

592

593

594






613 **Figure 3. Stepwise filtering identified microRNAs dysregulated in early OA and early RA.**

614 (A) Four sequential filtering criteria were applied to identify dysregulated microRNAs. The brown  
615 box shows filtering for microRNAs in early OA versus early RA and non-OA/RA. The purple box  
616 shows filtering for microRNAs in early RA versus early OA and non-OA/RA. (B) Heatmap  
617 depicting plasma levels of 12 microRNAs dysregulated in early OA and early RA. Z-scores  
618 represent standardized microRNA counts, with green indicating higher levels and red indicating  
619 lower levels.

620



621 **Figure 4. RT-qPCR validation of six microRNAs in early OA and early RA.** RT-qPCR was  
622 performed in N=8 early OA and N=6 early RA independent plasma samples. Relative microRNA  
623 levels represent fold-change in early RA (purple) normalized to average levels in early OA  
624 (brown). \*p<0.05; error bars = 95% confidence interval. (A,B) Two microRNAs were upregulated  
625 in early OA versus early RA. (C-F) Four microRNAs were upregulated in early RA versus early  
626 OA.

627

628

629

630

631

632

633

Cohort	Early OA	Early RA	Non-OA/RA	p-value
<b>Inclusion criteria</b>	Individuals with symptomatic knee OA and KL grade 0 or 1 as diagnosed by an orthopedic surgeon. <sup>16</sup>	Treatment-naïve individuals with <6 months of RA symptoms as diagnosed by a rheumatologist; ACPA = 42-1196 IU/mL. <sup>18</sup>	Individuals with no history of arthritis.	-
<b>N</b>	12	6	44	-
<b>Sex (female) N (%)</b>	6 (50.0)	2 (33.3)	22 (50.0)	0.43
<b>Race (white) N (%)</b>	12 (100.0)	4 (66.6)	42 (95.5)	<0.05
<b>Age (years) Mean (SD)</b>	49 (11.7)	56 (14.3)	57 (7.7)	<0.05
<b>BMI (kg/m<sup>2</sup>) Mean (SD)</b>	28 (4.9)	27 (3.9)	26 (2.8)	0.41

634

635 **Table 1. Characterization of the three study groups used for microRNA-sequencing.** P-  
636 value shows the significance between groups assessed by one-way ANOVA for continuous  
637 variables and Chi-square test for categorical variables. KL = Kellgren-Lawrence; ACPA = Anti-  
638 citrullinated protein antibody; SD = standard deviation; BMI = body mass index.

639

640

641

642

643

644

645

646

647

648

649

Group	Name	Sequence	Proportion		
			Early OA	Early RA	Non-OA/RA
Early OA	Novel miRNA EOA 1	uaagagggacggaggagg	0.50	0.33	0.40
	<b>Novel miRNA EOA 2</b>	<b>gaugccugggaguugcgauucg</b>	<b>0.75</b>	<b>0.17</b>	<b>0.06</b>
	Novel miRNA EOA 3	gacgcggcgccggcgccgca	0.50	0.17	0.32
Early RA	Novel miRNA ERA 1	uuaagagggacggaggagg	0.17	0.50	0.34
	<b>Novel miRNA ERA 2</b>	<b>uguaagugagaagcaaaagugg</b>	<b>0.00</b>	<b>0.50</b>	<b>0.38</b>
	<b>Novel miRNA ERA 3</b>	<b>uggggauagagcauugcc</b>	<b>0.00</b>	<b>0.50</b>	<b>0.12</b>
	<b>Novel miRNA ERA 4</b>	<b>uacugggauuuuggagcuucu</b>	<b>0.00</b>	<b>0.50</b>	<b>0.20</b>
	Novel miRNA ERA 5	guugggaguuuggcuggg	0.08	0.67	0.24
	Novel miRNA ERA 6	gguuccauaguguaguggu	0.17	0.67	0.22
	<b>Novel miRNA ERA 7</b>	<b>gggaaacucugguggaag</b>	<b>0.00</b>	<b>0.50</b>	<b>0.36</b>
	Novel miRNA ERA 8	caugaauggauuaugag	0.25	0.67	0.48
	Novel miRNA ERA 9	cagagauagggauguauc	0.17	0.67	0.16
	Novel miRNA ERA 10	agacgcggcgccggcgccg	0.25	0.67	0.44

650

651 **Table 2. MicroRNA-sequencing identified five novel microRNAs enriched in early OA and**

652 **early RA.** List of all novel microRNA sequences found in  $\geq 50\%$  of early OA or early RA samples.

653 Proportion = % of samples in each group that have the novel microRNA sequence. Bold = novel

654 microRNAs prioritized for early OA and early RA.

655

656

657

658

659

660


661

662

663

664 **Supplemental display items**

665



666 **Supplemental Figure 1. No distinct clustering is observed when microRNA-sequencing**

667 **data are stratified by age, sex, BMI, or race.** Principal component analysis plots of microRNA-

668 sequencing data stratified by (A) age, (B) sex, (C) BMI (<25 kg/m<sup>2</sup> = normal; 25-30 kg/m<sup>2</sup> =

669 overweight; >30 kg/m<sup>2</sup> = obese), and (D) race. Each dot represents a sample. Each axis

670 represents percentage variance for the principal component (PC).

671

672

673

674

675

676

677

678

679


680

681

682

683

684



685 **Supplemental Figure 2. Expression profiles of microRNAs in pairwise comparisons.**

686 Heatmaps depicting unsupervised hierarchical clustering of microRNAs in individual samples of  
687 each pairwise comparison: (A) early OA versus early RA, (B) early OA versus non-OA/RA, and  
688 (C) early RA versus non-OA/RA. Z-scores represent standardized microRNA counts, with green  
689 indicating higher levels and red indicating lower levels.

690

691

692

693

694

695

696

697

698

699

700


701

702

703

704

705



706 **Supplemental Figure 3. RT-qPCR for six microRNAs in early OA and early RA showing**  
707 **results inconsistent with sequencing data.** RT-qPCR was performed in N=8 early OA and N=6  
708 early RA independent plasma samples. Relative microRNA levels represent fold-change in early  
709 RA (purple) normalized to average levels in early OA (brown). Significance is denoted by a  
710 horizontal bar with \*p<0.05 or NS = non-significant. Error bars = 95% confidence interval.

711

712

713

714

715

716

717

Primer name	Primer Sequence (5'-3')
hsa-miR-16-5p	TCGCTTAGCAGCACGTAAATA
hsa-miR-21-5p	TCGCTTAGCTTATCAGACTGA
hsa-miR-24-3p	TGGCTCAGTTCAGCAGGAACAG
hsa-miR-29c-3p	TCGCTTAGCACCATTTGAAAT
hsa-miR-142-3p	TCGCTTGTAGTGTTCCTACTT
hsa-miR-144-3p	TCGCTTACAGTATAGATGA
hsa-miR-382-5p	TCGCTGAAGTTGTTCTGGTG
hsa-miR-486-3p	TCGCTCGGGCAGCTCAGTA
hsa-miR-486-5p	TCGCTTCCTGTAAGCTGC
hsa-miR-660-5p	TCGCTTACCCATTGCATATCG
hsa-miR-744-5p	TCGCTTGCGGGGCTAGGGCTA
hsa-miR-3074-5p	TCGCTGTTCTGCTGAACTG
hsa-miR-11400	TCGCTTCGGCTGTGTATCTCT
Oligo-dT adapter primer	GCATAGACCTGAATGGCGGTAAGGGTGT GGTAGGCGAGACATTTTTTTTTTTTTTTTTTTT
Universal microRNA reverse primer	GCATAGACCTGAATGGCGGTA

718

719 **Supplemental Table 1. List of primers for microRNA RT-qPCR.**

720

721

722



723

MicroRNA	Directionality in Early RA	Early RA versus Early OA				Early RA versus Non-OA/RA			
		logFC	logCPM	FDR	Proportion	logFC	logCPM	FDR	Proportion
hsa-miR-11400	Up	3.27	4.81	0.02	1.00	0.03	5.95	0.99	0.83
hsa-miR-21-5p	Up	1.26	10.50	0.00	1.00	0.28	10.96	0.41	0.83
hsa-miR-660-5p	Down	-0.95	7.76	0.00	1.00	-0.46	7.51	0.19	0.83
hsa-miR-29c-3p	Down	-0.77	8.35	0.02	1.00	-0.55	8.30	0.19	0.83

724

725 **Supplemental Table 2. Four microRNAs prioritized in early RA versus early OA and non-**

726 **OA/RA.** For directionality, “Up” reflects upregulation while “Down” reflects downregulation in early

727 RA versus early OA or non-OA/RA. For logFC, >0 reflects upregulation while ≤0 reflects

728 downregulation in early RA versus early OA or non-OA/RA. For FDR, ≤0.05 represents

729 statistically significant differential expression in the pairwise comparison. For proportion, values

730 represent the percentage of samples with logCPM either greater than (for upregulated

731 microRNAs) or less than (for downregulated microRNAs) the median logCPM of the comparison

732 group.

733

734

735

736

737

738

739

740

741

742

743

744

MicroRNA	Directionality in Early OA	Early OA versus Early RA				Early OA versus Non-OA/RA			
		logFC	logCPM	FDR	Proportion	logFC	logCPM	FDR	Proportion
hsa-miR-144-3p	Up	1.84	11.34	0.000	1.00	2.08	10.40	0.000	1.00
hsa-miR-486-3p	Up	1.61	13.39	0.000	1.00	2.36	12.31	0.000	1.00
hsa-miR-486-5p	Up	1.34	15.10	0.002	1.00	2.20	14.05	0.000	1.00
hsa-miR-16-5p	Up	1.27	18.83	0.000	1.00	1.67	18.03	0.000	1.00
hsa-miR-744-5p	Down	-2.88	10.38	0.000	1.00	-3.14	11.56	0.000	1.00
hsa-miR-382-5p	Down	-2.91	10.28	0.004	1.00	-2.83	11.14	0.000	1.00
hsa-miR-142-3p	Down	-2.90	10.08	0.000	1.00	-3.56	11.65	0.000	1.00
hsa-miR-3074-5p	Down	-2.61	10.93	0.000	1.00	-2.87	12.06	0.000	1.00

745

746 **Supplemental Table 3. Eight microRNAs prioritized in early OA versus early RA and non-**

747 **OA/RA.** For directionality, “Up” reflects upregulation while “Down” reflects downregulation in early

748 OA versus early RA or non-OA/RA. For logFC, >0 reflects upregulation while ≤0 reflects

749 downregulation in early OA versus early RA or non-OA/RA. For FDR, ≤0.05 represents

750 statistically significant differential expression in the pairwise comparison. For proportion, values

751 represent the percentage of samples with logCPM either greater than (for upregulated

752 microRNAs) or less than (for downregulated microRNAs) the median logCPM of the comparison

753 group.

754

755

756

757

758

759

760

761

762

Cohort	Early OA	Early RA	p-value
N	8	6	-
Sex (female) N (%)	2 (25)	2 (33.3)	1
Race (white) N (%)	8 (100)	5 (83.3)	0.89
Age (years) Mean (SD)	24 (5.3)	63 (9.4)	<0.05
BMI (kg/m <sup>2</sup> ) Mean (SD)	30 (8.5)	26 (2.9)	0.30

763

764 **Supplemental Table 4. Characterization of the two study groups used for microRNA RT-**

765 **qPCR.** N = sample size; SD = standard deviation; BMI = body mass index.

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780